Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Dec;81(7):1182–1187. doi: 10.1038/sj.bjc.6690827

Epstein–Barr virus expression in Hodgkin’s disease in relation to patient characteristics, serum factors and blood lymphocyte function

U Axdorph 1, A Porwit-MacDonald 2, J Sjöberg 1, G Grimfors 1, M Ekman 2, W Wang 2, P Biberfeld 2, M Björkholm 1
PMCID: PMC2374328  PMID: 10584880

Abstract

Epstein–Barr virus (EBV) expression was investigated by immunohistochemistry (latent membrane protein 1 [LMP-1]) and in situ hybridization (EBV encoded RNA [EBER]) in biopsies from 95 patients with untreated Hodgkin’s disease (HD). Tumour EBV status was related to EBV antibody titres, spontaneous and concanavallin A induced blood lymphocyte DNA synthesis, serum levels of soluble (s) CD4, sCD8, sCD25, sCD30, sCD54, β2-microglobulin, thymidine-kinase, routine chemistry, patient characteristics, complete remission and survival. The median follow-up time was 145 months (range 60–257). Tumour EBV-positive (n = 30; 33%) and negative (n = 62; 67%) patients did not differ with regard to sex, age, stage, presence of bulky disease or B-symptoms, remission rate or survival. The proportion of EBV+ cases was significantly higher among patients with mixed cellularity histopathology (58%) as compared to the nodular sclerosis subtype (18%; P < 0.001). The total white blood cell (WBC) counts were significantly lower in EBV+ patients (P < 0.01), who also had significantly higher levels of sCD54 (P < 0.02) and a tendency towards lower levels of sCD30 (P = 0.056). Patients in the tumour EBV+ group had significantly higher IgG antibody titres to restricted early antigen (EA-R) (P < 0.02). Hence, clinical features and outcome were not related to tumour EBV status. However, HD patients with EBV+ tumours had elevated sCD54 levels, higher antibody titres to EA-R and decreased total WBC counts. A potential causal relationship between EBV tumour status and these findings needs to be further explored. © 1999 Cancer Research Campaign

Keywords: Epstein–Barr virus, Hodgkin’s disease, lymphocyte function, prognosis, sCD30, s-ICAM-1

Full Text

The Full Text of this article is available as a PDF (82.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bibeau F., Brousset P., Knecht H., Meggetto F., Drouet E., Rubin B., Delsol G. Réplication du virus d'Epstein-Barr dans la maladie de Hodgkin. Bull Cancer. 1994 Feb;81(2):114–118. [PubMed] [Google Scholar]
  2. Björkholm M., Axdorph U., Grimfors G., Merk K., Johansson B., Landgren O., Svedmyr E., Mellstedt H., Holm G. Fixed versus response-adapted MOPP/ABVD chemotherapy in Hodgkin's disease. A prospective randomized trial. Ann Oncol. 1995 Nov;6(9):895–899. doi: 10.1093/oxfordjournals.annonc.a059356. [DOI] [PubMed] [Google Scholar]
  3. Björkholm M., Holm G., Mellstedt H., Johansson B., Askergren J., Söderberg G. Prognostic factors in Hodgkin's disease. I. Analysis of histopathology, stage distribution and results of therapy. Scand J Haematol. 1977 Nov;19(5):487–495. [PubMed] [Google Scholar]
  4. Björkholm M., Holm G., Mellstedt H., Johansson B., Killander D., Sunblad R., Söderberg G. Prognostic factors in Hodgkin's disease. II. Role of the lymphocyte defect. Scand J Haematol. 1978 Apr;20(4):306–318. [PubMed] [Google Scholar]
  5. Brousset P., Knecht H., Rubin B., Drouet E., Chittal S., Meggetto F., Saati T. A., Bachmann E., Denoyel G., Sergeant A. Demonstration of Epstein-Barr virus replication in Reed-Sternberg cells of Hodgkin's disease. Blood. 1993 Aug 1;82(3):872–876. [PubMed] [Google Scholar]
  6. Carbone P. P., Kaplan H. S., Musshoff K., Smithers D. W., Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res. 1971 Nov;31(11):1860–1861. [PubMed] [Google Scholar]
  7. Cordell J. L., Falini B., Erber W. N., Ghosh A. K., Abdulaziz Z., MacDonald S., Pulford K. A., Stein H., Mason D. Y. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem. 1984 Feb;32(2):219–229. doi: 10.1177/32.2.6198355. [DOI] [PubMed] [Google Scholar]
  8. Dougherty G. J., Murdoch S., Hogg N. The function of human intercellular adhesion molecule-1 (ICAM-1) in the generation of an immune response. Eur J Immunol. 1988 Jan;18(1):35–39. doi: 10.1002/eji.1830180107. [DOI] [PubMed] [Google Scholar]
  9. Enblad G., Sandvej K., Lennette E., Sundström C., Klein G., Glimelius B., Pallesen G. Lack of correlation between EBV serology and presence of EBV in the Hodgkin and Reed-Sternberg cells of patients with Hodgkin's disease. Int J Cancer. 1997 Jul 29;72(3):394–397. doi: 10.1002/(sici)1097-0215(19970729)72:3<394::aid-ijc3>3.0.co;2-k. [DOI] [PubMed] [Google Scholar]
  10. Frisan T., Sjöberg J., Dolcetti R., Boiocchi M., De Re V., Carbone A., Brautbar C., Battat S., Biberfeld P., Eckman M. Local suppression of Epstein-Barr virus (EBV)-specific cytotoxicity in biopsies of EBV-positive Hodgkin's disease. Blood. 1995 Aug 15;86(4):1493–1501. [PubMed] [Google Scholar]
  11. Grimfors G., Andersson B., Tullgren O., Giscombe R., Holm G., Johansson B., Björkholm M. Increased serum CD8 soluble antigen level is associated with blood lymphocyte abnormalities and other established indicators of a poor prognosis in adult Hodgkin's disease. Br J Haematol. 1992 Feb;80(2):166–171. doi: 10.1111/j.1365-2141.1992.tb08895.x. [DOI] [PubMed] [Google Scholar]
  12. Groux H., Bigler M., de Vries J. E., Roncarolo M. G. Interleukin-10 induces a long-term antigen-specific anergic state in human CD4+ T cells. J Exp Med. 1996 Jul 1;184(1):19–29. doi: 10.1084/jem.184.1.19. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Gruss H-J, Herrmann F. CD30 ligand, a member of the TNF ligand superfamily, with growth and activation control CD30+ lymphoid and lymphoma cells. Leuk Lymphoma. 1996 Feb;20(5-6):397–409. doi: 10.3109/10428199609052421. [DOI] [PubMed] [Google Scholar]
  14. Gruss H. J., Scheffrahn I., Hubinger G., Duyster J., Hermann F. The CD30 ligand and CD40 ligand regulate CD54 surface expression and release of its soluble form by cultured Hodgkin and Reed-Sternberg cells. Leukemia. 1996 May;10(5):829–835. [PubMed] [Google Scholar]
  15. Harris N. L. A practical approach to the pathology of lymphoid neoplasms: a revised European-American classification from the International Lymphoma Study Group. Important Adv Oncol. 1995:111–140. [PubMed] [Google Scholar]
  16. Henle W., Henle G. E., Horwitz C. A. Epstein-Barr virus specific diagnostic tests in infectious mononucleosis. Hum Pathol. 1974 Sep;5(5):551–565. doi: 10.1016/s0046-8177(74)80006-7. [DOI] [PubMed] [Google Scholar]
  17. Herbst H., Dallenbach F., Hummel M., Niedobitek G., Pileri S., Müller-Lantzsch N., Stein H. Epstein-Barr virus latent membrane protein expression in Hodgkin and Reed-Sternberg cells. Proc Natl Acad Sci U S A. 1991 Jun 1;88(11):4766–4770. doi: 10.1073/pnas.88.11.4766. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Herbst H., Foss H. D., Samol J., Araujo I., Klotzbach H., Krause H., Agathanggelou A., Niedobitek G., Stein H. Frequent expression of interleukin-10 by Epstein-Barr virus-harboring tumor cells of Hodgkin's disease. Blood. 1996 Apr 1;87(7):2918–2929. [PubMed] [Google Scholar]
  19. Kaczorowski S., Kaczorowska M., Christensson B. Expression of EBV encoded latent membrane protein 1 (LMP-1) and bcl-2 protein in childhood and adult Hodgkin's disease: application of microwave irradiation for antigen retrieval. Leuk Lymphoma. 1994 Apr;13(3-4):273–283. doi: 10.3109/10428199409056291. [DOI] [PubMed] [Google Scholar]
  20. Kanavaros P., Jiwa M., van der Valk P., Walboomers J., Horstman A., Meijer C. J. Expression of Epstein-Barr virus latent gene products and related cellular activation and adhesion molecules in Hodgkin's disease and non-Hodgkin's lymphomas arising in patients without overt pre-existing immunodeficiency. Hum Pathol. 1993 Jul;24(7):725–729. doi: 10.1016/0046-8177(93)90008-5. [DOI] [PubMed] [Google Scholar]
  21. Khanna R., Burrows S. R., Nicholls J., Poulsen L. M. Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1): evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes. Eur J Immunol. 1998 Feb;28(2):451–458. doi: 10.1002/(SICI)1521-4141(199802)28:02<451::AID-IMMU451>3.0.CO;2-U. [DOI] [PubMed] [Google Scholar]
  22. Knecht H., McQuain C., Martin J., Rothenberger S., Drexler H. G., Berger C., Bachmann E., Kittler E. L., Odermatt B. F., Quesenberry P. J. Expression of the LMP1 oncoprotein in the EBV negative Hodgkin's disease cell line L-428 is associated with Reed-Sternberg cell morphology. Oncogene. 1996 Sep 5;13(5):947–953. [PubMed] [Google Scholar]
  23. Lauritzen A. F., Hørding U., Nielsen H. W. Epstein-Barr virus and Hodgkin's disease: a comparative immunological, in situ hybridization, and polymerase chain reaction study. APMIS. 1994 Jul;102(7):495–500. doi: 10.1111/j.1699-0463.1994.tb05196.x. [DOI] [PubMed] [Google Scholar]
  24. Levine P. H., Pallesen G., Ebbesen P., Harris N., Evans A. S., Müeller N. Evaluation of Epstein-Barr virus antibody patterns and detection of viral markers in the biopsies of patients with Hodgkin's disease. Int J Cancer. 1994 Oct 1;59(1):48–50. doi: 10.1002/ijc.2910590111. [DOI] [PubMed] [Google Scholar]
  25. MacLennan K. A., Bennett M. H., Tu A., Hudson B. V., Easterling M. J., Hudson G. V., Jelliffe A. M. Relationship of histopathologic features to survival and relapse in nodular sclerosing Hodgkin's disease. A study of 1659 patients. Cancer. 1989 Oct 15;64(8):1686–1693. doi: 10.1002/1097-0142(19891015)64:8<1686::aid-cncr2820640822>3.0.co;2-i. [DOI] [PubMed] [Google Scholar]
  26. Makgoba M. W., Sanders M. E., Ginther Luce G. E., Dustin M. L., Springer T. A., Clark E. A., Mannoni P., Shaw S. ICAM-1 a ligand for LFA-1-dependent adhesion of B, T and myeloid cells. Nature. 1988 Jan 7;331(6151):86–88. doi: 10.1038/331086a0. [DOI] [PubMed] [Google Scholar]
  27. Makgoba M. W., Sanders M. E., Ginther Luce G. E., Gugel E. A., Dustin M. L., Springer T. A., Shaw S. Functional evidence that intercellular adhesion molecule-1 (ICAM-1) is a ligand for LFA-1-dependent adhesion in T cell-mediated cytotoxicity. Eur J Immunol. 1988 Apr;18(4):637–640. doi: 10.1002/eji.1830180423. [DOI] [PubMed] [Google Scholar]
  28. Marlin S. D., Springer T. A. Purified intercellular adhesion molecule-1 (ICAM-1) is a ligand for lymphocyte function-associated antigen 1 (LFA-1). Cell. 1987 Dec 4;51(5):813–819. doi: 10.1016/0092-8674(87)90104-8. [DOI] [PubMed] [Google Scholar]
  29. Mehta C. R., Patel N. R., Tsiatis A. A. Exact significance testing to establish treatment equivalence with ordered categorical data. Biometrics. 1984 Sep;40(3):819–825. [PubMed] [Google Scholar]
  30. Morente M. M., Piris M. A., Abraira V., Acevedo A., Aguilera B., Bellas C., Fraga M., Garcia-Del-Moral R., Gomez-Marcos F., Menarguez J. Adverse clinical outcome in Hodgkin's disease is associated with loss of retinoblastoma protein expression, high Ki67 proliferation index, and absence of Epstein-Barr virus-latent membrane protein 1 expression. Blood. 1997 Sep 15;90(6):2429–2436. [PubMed] [Google Scholar]
  31. Mueller N., Evans A., Harris N. L., Comstock G. W., Jellum E., Magnus K., Orentreich N., Polk B. F., Vogelman J. Hodgkin's disease and Epstein-Barr virus. Altered antibody pattern before diagnosis. N Engl J Med. 1989 Mar 16;320(11):689–695. doi: 10.1056/NEJM198903163201103. [DOI] [PubMed] [Google Scholar]
  32. Murray R. J., Wang D., Young L. S., Wang F., Rowe M., Kieff E., Rickinson A. B. Epstein-Barr virus-specific cytotoxic T-cell recognition of transfectants expressing the virus-coded latent membrane protein LMP. J Virol. 1988 Oct;62(10):3747–3755. doi: 10.1128/jvi.62.10.3747-3755.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Nadali G., Vinante F., Ambrosetti A., Todeschini G., Veneri D., Zanotti R., Meneghini V., Ricetti M. M., Benedetti F., Vassanelli A. Serum levels of soluble CD30 are elevated in the majority of untreated patients with Hodgkin's disease and correlate with clinical features and prognosis. J Clin Oncol. 1994 Apr;12(4):793–797. doi: 10.1200/JCO.1994.12.4.793. [DOI] [PubMed] [Google Scholar]
  34. Nakagomi H., Dolcetti R., Bejarano M. T., Pisa P., Kiessling R., Masucci M. G. The Epstein-Barr virus latent membrane protein-1 (LMP1) induces interleukin-10 production in Burkitt lymphoma lines. Int J Cancer. 1994 Apr 15;57(2):240–244. doi: 10.1002/ijc.2910570218. [DOI] [PubMed] [Google Scholar]
  35. Pallesen G., Hamilton-Dutoit S. J., Rowe M., Young L. S. Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease. Lancet. 1991 Feb 9;337(8737):320–322. doi: 10.1016/0140-6736(91)90943-j. [DOI] [PubMed] [Google Scholar]
  36. Pinkus G. S., Lones M., Shintaku I. P., Said J. W. Immunohistochemical detection of Epstein-Barr virus-encoded latent membrane protein in Reed-Sternberg cells and variants of Hodgkin's disease. Mod Pathol. 1994 May;7(4):454–461. [PubMed] [Google Scholar]
  37. Pizzolo G., Vinante F., Nadali G., Ricetti M. M., Morosato L., Marrocchella R., Vincenzi C., Semenzato G., Chilosi M. ICAM-1 tissue overexpression associated with increased serum levels of its soluble form in Hodgkin's disease. Br J Haematol. 1993 May;84(1):161–162. doi: 10.1111/j.1365-2141.1993.tb03040.x. [DOI] [PubMed] [Google Scholar]
  38. Reedman B. M., Klein G. Cellular localization of an Epstein-Barr virus (EBV)-associated complement-fixing antigen in producer and non-producer lymphoblastoid cell lines. Int J Cancer. 1973 May;11(3):499–520. doi: 10.1002/ijc.2910110302. [DOI] [PubMed] [Google Scholar]
  39. Sandvej K. B., Hamilton-Dutoit S. J., Pallesen G. Influence of Epstein-Barr virus encoded latent membrane protein 1 on the expression of CD23 antigen, ICAM-1 and LFA-3 in Hodgkin and Reed-Sternberg cells. A morphometric analysis. Leuk Lymphoma. 1993 Jan;9(1-2):95–101. doi: 10.3109/10428199309148510. [DOI] [PubMed] [Google Scholar]
  40. Tullgren O., Grimfors G., Holm G., Johansson B., Svedmyr E., Wedelin C., Mellstedt H., Merk K., Björkholm M. Lymphocyte abnormalities predicting a poor prognosis in Hodgkin's disease. A long-term follow-up. Cancer. 1991 Aug 15;68(4):768–775. doi: 10.1002/1097-0142(19910815)68:4<768::aid-cncr2820680418>3.0.co;2-1. [DOI] [PubMed] [Google Scholar]
  41. Vestlev P. M., Pallesen G., Sandvej K., Hamilton-Dutoit S. J., Bendtzen S. M. Prognosis of Hodgkin's disease is not influenced by Epstein-Barr virus latent membrane protein. Int J Cancer. 1992 Feb 20;50(4):670–671. doi: 10.1002/ijc.2910500432. [DOI] [PubMed] [Google Scholar]
  42. Wang D., Liebowitz D., Kieff E. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell. 1985 Dec;43(3 Pt 2):831–840. doi: 10.1016/0092-8674(85)90256-9. [DOI] [PubMed] [Google Scholar]
  43. Wang D., Liebowitz D., Wang F., Gregory C., Rickinson A., Larson R., Springer T., Kieff E. Epstein-Barr virus latent infection membrane protein alters the human B-lymphocyte phenotype: deletion of the amino terminus abolishes activity. J Virol. 1988 Nov;62(11):4173–4184. doi: 10.1128/jvi.62.11.4173-4184.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Wedelin C., Björkholm M., Holm G., Ogenstad S., Johansson B., Mellstedt H. Lymphocyte function in untreated Hodgkin's disease: an important predictor of prognosis. Br J Cancer. 1982 Jan;45(1):70–79. doi: 10.1038/bjc.1982.9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Wu T. C., Mann R. B., Epstein J. I., MacMahon E., Lee W. A., Charache P., Hayward S. D., Kurman R. J., Hayward G. S., Ambinder R. F. Abundant expression of EBER1 small nuclear RNA in nasopharyngeal carcinoma. A morphologically distinctive target for detection of Epstein-Barr virus in formalin-fixed paraffin-embedded carcinoma specimens. Am J Pathol. 1991 Jun;138(6):1461–1469. [PMC free article] [PubMed] [Google Scholar]
  46. Younes A., Consoli U., Snell V., Clodi K., Kliche K. O., Palmer J. L., Gruss H. J., Armitage R., Thomas E. K., Cabanillas F. CD30 ligand in lymphoma patients with CD30+ tumors. J Clin Oncol. 1997 Nov;15(11):3355–3362. doi: 10.1200/JCO.1997.15.11.3355. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES